Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.
Obesity (Silver Spring)Jul 30, 2026 (epub)
W Timothy Garvey, Julio Rosenstock, Harold E Bays et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the safety, tolerability, pharmacokinetics, and efficacy of TERN-601, an oral GLP-1 receptor agonist, in adults with obesity or overweight through Phase 1 and 2 randomized controlled trials. Results showed that doses ≥500 mg led to significantly greater mean percentage weight loss at Week 12 compared to placebo.
Key findings
- TERN-601 produced dose-dependent weight loss over 28 days in the Phase 1 study.
- In the Phase 2 study, doses ≥500 mg resulted in significantly greater mean percentage weight loss at Week 12 versus placebo.
- Gastrointestinal treatment-emergent adverse events were consistent with the GLP-1 receptor agonist class.
Why it matters
Understanding the efficacy and safety profile of oral GLP-1 receptor agonists like TERN-601 is crucial for managing obesity, a significant public health concern. Insights from this study can inform future research and treatment strategies.
What to keep in mind
The study was discontinued due to liver safety concerns observed in the Phase 2 trial.